Cooperative Agreement HU0001262E071

The DOD Uniformed Services University of the Health Sciences awarded The Geneva Foundation a $259,805 cooperative agreement on August 1, 2026, for independent verification and validation of the Medics Autonomously Stopping Hemorrhage (MASH) program under the Uniformed Services University Medical Research Projects program (CFDA 12.750). The work is performed in the United States with a period of performance through July 31, 2027. The cooperative agreement funds evaluation and verification...

The Texas A&M Engineering Experiment Station (Tees) was awarded a $2,404,778 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will support research and development of expandable hemostats for treatment of noncompressible intracaivitary hemorrhage from August 15, 2022 to August 14, 2026. Through this funding, Tees will investigate medical solutions for uncontrolled bleeding on the battlefield,...

The U.S. Department of Defense (DoD) Defense Health Agency awarded a $1,820,004 Project Grant to Case Western Reserve University's Office of Research Administration Division, doing business as the University Hospitals of Cleveland, under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "HEMOSEAL: COMBINATORIAL NANOPARTICLE TECHNOLOGY FOR POINT-OF-INJURY HEMORRHAGE CONTROL," will support the development of an innovative nanoparticle-based technology...

This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $4,000,000.00 in funding to Medcura, Inc. in Riverdale, MD to expand the development and production of a biopolymer powder treatment for noncompressible torso hemorrhage. The research aims to improve health outcomes for military service members and the broader public by advancing this innovative medical technology. The award period extends from Aug 5,...

The Department of the Army Medical Command awarded Cayuga Biotech Inc. a $922,870 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will support Cayuga Biotech's development of an intravenous agent for traumatic hemorrhage control from July 1, 2021 to June 30, 2022. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions, including investigations into...

The National Institute of Biomedical Imaging and Bioengineering, part of the Department of Health and Human Services National Institutes of Health, awarded Massachusetts General Hospital $2,007,744 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop MSEAL, a supramolecular surgical sealant for hemostasis in burn excision surgery. MSEAL is a spray-on, highly adhesive sealant engineered to address...

The Defense Advanced Research Projects Agency awarded Massachusetts Institute of Technology a $1.362 million cooperative agreement on January 21, 2026, under the Research and Technology Development program (CFDA 12.910) to design and develop advanced integrated ultrasound for hemorrhage diagnostic and targeted drug delivery using nanoparticles for combat casualty care. The award is a DARPA Seedling project. Performance will occur in Cambridge, Massachusetts through January 20, 2027. The...

The Defense Advanced Research Projects Agency awarded a Cooperative Agreement to Carnegie Mellon University for $497,430 on March 24, 2026, under the Research and Technology Development program (CFDA 12.910) to develop hands-on robot casualty care systems under the Robot Medic Seedling initiative. Performance runs through October 23, 2026, at Carnegie Mellon's Pittsburgh, Pennsylvania location. The award supports applied research and advanced development in robotic systems for medical casualty...

The University of Maryland, Baltimore received a $308,821 Project Grant award from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund the development of a novel medical device called the TRANSESOPHAGEAL AORTIC BLOOD FLOW OCCLUDER to control non-compressible torso hemorrhage from January 15, 2022 to January 14, 2024. The device aims to transform trauma care for service members and the public through innovative...

Federal Project Grant Award Summary Vascular Perfusion Solutions Inc. received an $818,337 Project Grant award dated August 15, 2025, from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The award supports research and development of extended limb stasis capabilities within the ENCORE Tissue Preservation Device, with performance through August 14, 2027, at the awardee's San Antonio, Texas facility. This modification to the existing award...